Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 6/20 | 0.52 |
| ▸ | HTR2B | P41595 | 5/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | ABL2 | P42684 | 2/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5167485 | 0.88 | HTR3E (0.43) | IKBKBHTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL5165736 | 0.88 | HTR3E (0.43) | IKBKBHTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL5167764 | 0.88 | HTR3E (0.43) | IKBKBHTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL14540204 | 0.88 | HTR3E (0.43) | IKBKBHTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL5163731 | 0.87 | IKBKB (0.52) | IKBKBHTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL5165119 | 0.86 | IKBKB (0.50) | IKBKBHTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL5165177 | 0.84 | IKBKB (0.40) | IKBKBHTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL5165853 | 0.82 | IKBKB (0.40) | IKBKBHTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL14414772 | 0.81 | IKBKB (0.46) | IKBKBHTR2BHTR2CHTR2APARP1 | |
| SCHEMBL5164179 | 0.80 | IKBKB (0.41) | IKBKBHTR2BHTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | PFIZER INC. | 2007-09-27 | — | — | US | claimed |
| EP-1678164-B1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-04-11 | — | — | EP | claimed |
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | PFIZER INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | PFIZER INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | PFIZER INC. | 2007-09-27 | — | — | US | disclosed |
| EP-1678164-B1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1678164-B1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | CNKSR1, IL1RN, CHUK | IKBKB 15/4885HTR2B 3001/4885HTR3E 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.